Alector (ALEC) Income from Continuing Operations (2018 - 2026)
Alector (ALEC) reported Income from Continuing Operations of 22930000.0 for Q1 2026, up 43.34% year-over-year from 15996690.86 in Q1 2025, and up 38.47% quarter-over-quarter from 37267000.0 in Q4 2025.
Alector (ALEC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Income from Continuing Operations data on file, last reported at 22930000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 22930000.0, up 43.34% year-over-year; the trailing twelve-month figure through Mar 2026 was 125388000.0 (down 1.68% YoY), and the FY2025 annual result was 142929000.0, down 20.19% from the prior year.
- Income from Continuing Operations climbed to 22930000.0 in Q1 2026 per ALEC's latest filing, from 37267000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9883000.0 in Q2 2022 and troughed at 51383000.0 in Q4 2022.
- A 5-year average of 32141294.12 and a median of 38676000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations soared 117.92% in 2022, then tumbled 2912.8% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 51383000.0 in 2022, then gained by 21.37% to 40400000.0 in 2023, then jumped by 95.18% to 1946000.0 in 2024, then tumbled by 1815.06% to 37267000.0 in 2025, then surged by 38.47% to 22930000.0 in 2026.
- Business Quant data shows ALEC's Income from Continuing Operations at 22930000.0 in Q1 2026, 37267000.0 in Q4 2025, and 34667000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Alector | 193.53 Mn | -12.98 Mn | - | -22.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.93 Mn |
| Dec 31, 2025 | -37.27 Mn |
| Sep 30, 2025 | -34.67 Mn |
| Jun 30, 2025 | -30.52 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | -42.22 Mn |
| Jun 30, 2024 | -38.68 Mn |
| Mar 31, 2024 | -36.08 Mn |
| Dec 31, 2023 | -40.40 Mn |
| Sep 30, 2023 | -44.48 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | -45.86 Mn |
| Dec 31, 2022 | -51.38 Mn |
| Sep 30, 2022 | -46.15 Mn |
| Jun 30, 2022 | 9.88 Mn |
| Mar 31, 2022 | -44.62 Mn |
| Dec 31, 2021 | -55.61 Mn |
| Sep 30, 2021 | 126.60 Mn |
| Jun 30, 2021 | -55.15 Mn |